Skip to main content
FEMY logo

FEMY · Femasys Inc

Track FEMY — free
$1.12 -0.16 (-12.50%) At close · Nov 17
Market Cap
$9.70M
Shares
8.66M
Volume · Nov 17 110.56K Avg daily vol (3M) 695.5K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.12 Open$1.29 Day$1.07–1.31 52W close$1.12–20.20 Avg vol 30d102K Short int49K · 0.6% of shares · 1.0d Short vol46% Last earningsMar 21, 2024 DataJun 2021–Nov 2026 Filing10-Q · Nov 13

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sales fall 21.5% as nine-month net loss narrows

Femasys reported nine-month sales of $1,161,313, down 21.5%, and a net loss of $8,187,810, narrowed from $14,677,582. Cash and cash equivalents stood at $23,913,946 as of September 30, 2026.

Revenue $404.6K ▼ 44.5% Net loss $4.56M Diluted EPS -$0.53
Read from the MD&A section
3 source passages
Sales | 1,161,313 | | 1,479,926 | | (318,613) | | (21.5)% Net loss | (8,187,810) | | (14,677,582) | | 6,489,772 | | (44.2)% As of September 30, 2026, we had $23,913,946 of cash and cash equivalents and an accumulated deficit of $154,013,954. Open the document at this passage
Nov 13
Current report 8-K
Private placement funds commercial expansion despite sales decline

Femasys completed a $30 million private placement to fund U.S. commercial expansion; overall sales fell 44.5% to $404,597, net loss was $4,564,815, and cash was approximately $23.9 million as of September 30, 2026.

Financial results
4 source passages
Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed^®^ fertility portfolio to OB/GYNs, and to fund the FemBloc^®^ pivotal trial to support U.S. approval. Sales in the U.S.<br>increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025. Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 30
John Moorhead joins board as independent Class II director

Femasys Inc. appointed John Moorhead as an independent Class II director on October 30, 2026; Kenneth D. Eichenbaum also resigned as a director that day without dispute.

Director or officer change, or executive pay, Regulation FD disclosure
3 source passages
On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E., informed the Board of Directors (the “Board”) of Femasys Inc. (the “Company”) of his resignation as a director of the Company, effective as of that date. On October 30, 2026, the Board appointed John Moorhead as a director of the Company, effective as of that date. Mr. Moorhead will hold office as a Class II director for a term expiring at the 2029 annual meeting, at which time he will stand for election by the stockholders of the Company. The Board determined that Mr. Moorhead is an independent director for purposes of the Nasdaq listing requirements and will serve as a member of the Audit Committee and Compensation Committee of the Company. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.97M
Trailing 12 months
Net income (TTM)
−$12.14M
Trailing 12 months
Revenue growth YoY
-44.5%
Year over year
Operating margin
-929.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-178.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$23.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+322.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.6%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −80%
below
Price vs 50-day avg −41%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −33%
trailing
6-month return −85%
trailing
YTD return −90%
this year
Relative strength −82%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+56% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.57% of shares out · ▼ -70.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Squeeze score 33
low risk · 0–100
Fundamentals
Strong
Revenue growth +41%
Y/Y
Gross margin 33%
contracting
EPS growth +45%
Y/Y
Free cash flow $-19.2M
Quant / Vol
risk profile
Very High
Volatility 100%
annualized · 1-yr
Max drawdown −94%
past year
ATR 14.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−80% Bearish
Price vs 50-day avg
−41% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+56% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.57% of shares out · ▼ -70.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $20
vs 200-day avg -80% vs 50-day avg -41%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FEMY
Femasys Inc
this stock
$9.70M — +40.8% — 0.6%
ISRG
Intuitive Surgical Inc
$149.24B -24.0% +20.5% 52.2 2.0%
BDX
Becton Dickinson & Co
$58.68B — +8.2% 95.3 3.0%
MDLN
Medline Inc.
$49.56B -10.3% +11.5% — 2.9%
ALC
Alcon Inc
$35.60B -6.0% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
75.9%
Net QoQ
+4.5M sh
Top holder
Dauntless Investment Grou…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
49.3K
Days to cover
1.0d
Change
-114.8K sh
View
Short Volume
Short vol %
46%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
226
Value
$319
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
56.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.3M
Net income (FY)
$-18.6M
EPS diluted
$-9.40
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
25

Femasys completed a $30 million private placement to fund U.S. commercial expansion; overall sales fell 44.5% to $404,597, net loss was $4,564,815, and cash was approximately $23.9 million as of September 30, 2026.

View
Exempt Offerings
Offering
$30.0M
Filed
Aug 20, 2026
View
Earnings & Events
Webcasts
Last webcast
Mar 21, 2024
View
Investor Relations
Latest news
Femasys Announces Financial Resul…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
FEMY -21.7% -32.9% -85.3% -18.3% -90.3%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -19.4% -28.2% -82.3% -15.2% -97.7%
Key facts CIK 1339005 CUSIP 31447E204 13F (30d) 26 filings 26 filers Visit website Investor relations